What Happened? Shares of health insurance company Oscar Health (NYSE:OSCR) jumped 1.8% in the afternoon session after the government announced a surprise inc...
When the S&P 500 was flirting with 7,000 back in January, everyone wanted in. Now, with the index 400 to 500 points lower, the mood has flipped to fear. That disconnect between price and psychology is exactly where contrarian investors Jeff Clark of TradeSmith and Andy Swan of LikeFolio see opportunity.
Small-cap stocks in the Russell 2000 (^RUT) can be a goldmine for investors looking beyond the usual large-cap names. But with less stability and fewer resou...
What Happened? A number of stocks fell in the afternoon session after major indices including the S&P 500 and Dow Jones Industrial Average fell sharply as in...
Oscar Health has gotten torched over the last six months - since September 2025, its stock price has dropped 32.6% to $12.19 per share. This may have investo...
Small-cap stocks can be incredibly lucrative investments because their lack of analyst coverage leads to frequent mispricings. However, these businesses (and...
The end of the earnings season is always a good time to take a step back and see who shined (and who not so much). Let’s take a look at how health insurance ...
Running at a loss can be a red flag. Many of these businesses face mounting challenges as competition increases and funding becomes harder to secure. A lack ...
A number of stocks fell in the morning session after the Trump administration's announcement of new global tariffs reignited trade policy uncertainty. The move came swiftly after the Supreme Court ruled the previous week that the president could not use the International Emergency Economic Powers Act (IEEPA) for such duties, a decision that had initially sent markets higher. However, the administration invoked a different authority, the Trade Act of 1974, to impose a 15% global tariff for up to 150 days. The rapid reimposition of trade barriers creates significant uncertainty for companies across multiple sectors that depend on international supply chains and global trade. Investors are now weighing the potential impact of these new duties on corporate earnings and broader economic activity.
A highly volatile stock can deliver big gains - or just as easily wipe out a portfolio if things go south.
While some investors embrace risk, mistakes can be costly for those who aren’t prepared.
Oscar Health’s fourth quarter results drew a positive market response, despite revenue and earnings missing Wall Street expectations. Management attributed the miss to higher claims costs and increased risk adjustment payables, which reflected broader shifts in the Affordable Care Act (ACA) market. CEO Mark Bertolini cited the influx of Medicaid members and industry-wide changes in market morbidity as primary drivers, emphasizing that the company’s disciplined pricing and operational efficiency, including expanded AI deployment, helped offset some of these external headwinds. Bertolini stated, "Oscar embraced the change and positioned the company for strong top line growth and margin expansions in 2026."
Oscar Health Inc (NYSE:OSCR) shares are climbing on Thursday. The company posted fourth‑quarter results that missed expectations on both revenue and earnings, but had a stronger‑than‑expected 2026 outlook.
Health insurance company Oscar Health (NYSE:OSCR) missed Wall Street’s revenue expectations in Q4 CY2025, but sales rose 17.3% year on year to $2.81 billion. On the other hand, the company’s full-year revenue guidance of $18.85 billion at the midpoint came in 47.8% above analysts’ estimates. Its non-GAAP loss of $1.24 per share was 34.6% below analysts’ consensus estimates.
Shares of health insurance company Oscar Health (NYSE:OSCR) jumped 4.8% in the morning session after the company provided an optimistic financial outlook for 2026 that overshadowed its fourth-quarter 2025 earnings miss. The health insurer reported a fourth-quarter loss of $1.24 per share, which was wider than analyst estimates, while revenue of $2.81 billion also fell short of expectations. However, investors looked past the mixed results and focused on the company's ambitious forecast. For the full year 2026, Oscar Health projected revenue of $18.85 billion at the midpoint, significantly higher than the analyst consensus of approximately $12.76 billion, signaling healthy demand for its products and services.
Health insurance company Oscar Health (NYSE:OSCR) fell short of the market’s revenue expectations in Q4 CY2025, but sales rose 17.3% year on year to $2.81 billion. On the other hand, the company’s full-year revenue guidance of $18.85 billion at the midpoint came in 47.8% above analysts’ estimates. Its GAAP loss of $1.24 per share was 43.7% below analysts’ consensus estimates.
